Monday, November 19, 2018
Home Business & Economics

Business & Economics

Australian Kazia Therapeutics Presents ‘Trial in Progress’ Data for Glioblastoma Study

Results for GDC-0084, an investigational drug being being developed by Australian- based and oncology-focused Kazia Therapeutics and currently in human trials for the treatment of patients with glioblastoma, the most common and most aggressive form of primary brain cancer in adults, and several other forms of brain cancer were presented during the annual meeting of the Society for Neuro-Oncology...

Isofol Initiates Pivotal Phase III Clinical Trial of Arfolitixorin for Metastatic Colorectal Cancer

Sweden-based Isofol Medical has initiated their pivotal Phase III clinical trial, called the ISO-CC-007 study, for the treatment of first-line (initial) metastatic colorectal cancer (mCRC). Arfolitixorin is a new drug candidate primarily developed to increase the efficacy of the cytotoxic agent 5‑fluorouracil (5-FU) in the treatment of patients with advanced colorectal cancer and as a rescue drug after high-dose methotrexate...

Daiichi Sankyo to Colaborate with Merck KGaA and Pfizer in Development of Trastuzumab Deruxtecan

This week Daiichi Sankyo confirmed a clinical research collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate trastuzumab deruxtecan*, an antibody-drug conjugate or ADC also known as DS-8201, in combination with avelumab (Bavencio®; EMD Serono/Pfizer), a human anti-programmed death ligand-1 (PD-L1) antibody, and a novel, investigational DNA damage response (DDR) inhibitor in patients with human epidermal growth factor...

Executives from American Express and J.P. Morgan Join St. Baldrick’s Foundation ‘s Board

The St. Baldrick's Foundation, the largest private funder of some of the most brilliant (clinical) research in childhood cancer, has added two new members to its board of directors. The new members, Jyoti Rai, Sr. Vice President of Global Talent, Leadership and Learning at American Express and Thomas Selquist, Managing Director at J.P. Morgan Private Bank, are expected to help...

Phase Ib/II Data of Durvalumab Plus Danvatirsen Shows Promise in Head and Neck Cancer

New clinical and safety results from a phase Ib/II trial in recurrent metastatic head and neck cancer, presented at the annual meeting of the European Society for Medical Oncology - ESMO 2018, shows that danvatirsen (formerly known as IONIS-STAT3-2.5Rx and also known as AZD9150), a Generation 2.5 antisense therapy targeting signal transducer and activator of transcription 3 (STAT3) being...

Novartis Plans to Acquire Endocyte to Expand Expertise in Radiopharmaceuticals

Earlier this month Swiss-based Novartis announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. The planned merger will expand Novartis' expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms. Targeted therapies Endocyte uses drug conjugation technology to develop targeted therapies with companion...

NanoValent Receives NIH SBIR Funding for Antibody-conjugated Nanoparticle Technology

The National Institute of Health's (NIH) Small Business Innovation Research (SBIR) Program has confirmed that it has awarded first year funding for two separate projects being developed by NanoValent Pharmaceuticals, a development-stage pharmaceutical company advancing targeted antibody-drug conjugate (ADC) like, lipid based therapeutics. The two grants, totaling just under US $ 4 million, are expected to help NanoValent Pharmaceuticals to...

Study Shows Trade and Patent Changes Could Increase Healthcare Cost by $100bn Over the Next 5-years

In the second part of its 2018 annual report, CPhI Worldwide, the world’s largest pharma event taking place later this year in Madrid, Spain, Dilip Shah, CEO of Vision Consulting Group, and Bikash Chatterjee, President and Chief Science Officer at Pharmatech Associates review the impact of IPRs and trade agreements and regulatory divergence respectively, suggesting the implications of both could...

Hemispherx Biopharma Releases Rintatolimod in EAP-program to Dutch Pancreatic Cancer Patients

Rintatolimod (Ampligen®; Hemispherx Biopharma) is a mismatched, double-stranded RNA molecule with immunomodulatory and antiviral properties. The drug acts as a Toll-like Receptor 3 (TLR3) agonists. TLR3s have been extensively used as adjuvants for anticancer vaccines. Rintatolimod stimulates the production of interferons and tumor necrosis factors and has shown to raise natural killer cell function. In a statement, Hemispherx Biopharma the...

Phase III Trial of Anti-PD-1 Antibody Tislelizumab + Chemotherapy Initiated as Treatment for NSCLC

BeiGene, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs, has dosed the first patient dosed in a Phase III clinical trial of tislelizumab, also known as BGB-A317,an investigational anti-PD-1 antibody, combined with chemotherapy, as a potential first-line treatment in China for patients with Stage IIIB or IV squamous non-small cell lung cancer (NSCLC). In...

Related articles